Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study - Wikidata - awgldk - TriplyDB

Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study

Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study

http://www.wikidata.org/entity/Q28300023

about

Preventive vaccination against cervical cancer: Korean Society of Gynecologic Oncology Guideline Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS)HPV infection and vaccination in Systemic Lupus Erythematosus patients: what we really should know Current global status & impact of human papillomavirus vaccination: Implications for India Long-term efficacy and safety of human papillomavirus vaccination Safety of human papillomavirus vaccines: a review Inadvisable anti-vaccination sentiment: Human Papilloma Virus immunisation falsely under the microscope.Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United States Quadrivalent human papillomavirus vaccine and autoimmune adverse events: a case-control assessment of the vaccine adverse event reporting system (VAERS) database.Current Safety Concerns with Human Papillomavirus Vaccine: A Cluster Analysis of Reports in VigiBase®A case-control study of quadrivalent human papillomavirus vaccine-associated autoimmune adverse events.Adverse event monitoring of the human papillomavirus vaccines in Scotland.Severe somatoform and dysautonomic syndromes after HPV vaccination: case series and review of literature.Immunisation Information Systems - useful tools for monitoring vaccination programmes in EU/EEA countries, 2016.School nurses' attitudes and experiences regarding the human papillomavirus vaccination programme in Sweden: a population-based survey.Should we target patients with autoimmune diseases for human papillomavirus vaccine uptake?HPV vaccination to prevent cervical cancer and other HPV-associated disease: from basic science to effective interventions.Educational interventions to increase HPV vaccination acceptance: a systematic review.Human papillomavirus vaccine uptake among individuals with systemic inflammatory diseases.Examining a possible association between human papilloma virus (HPV) vaccination and migraine: results of a cohort study in the Netherlands Genetics and vaccines in the era of personalized medicine.Vaccinations in paediatric rheumatology: an update on current developments.Adolescent Premature Ovarian Insufficiency Following Human Papillomavirus Vaccination: A Case Series Seen in General Practice Pre-Vaccination Care-Seeking in Females Reporting Severe Adverse Reactions to HPV Vaccine. A Registry Based Case-Control Study.Absence of venous thromboembolism risk following quadrivalent human papillomavirus vaccination, Vaccine Safety Datalink, 2008-2011.Impact of 2-, 4- and 9-valent HPV vaccines on morbidity and mortality from cervical cancer No evidence that HPV vaccination leads to sexual risk compensation.Is HPV vaccination in pregnancy safe?Risk of new onset autoimmune disease in 9- to 25-year-old women exposed to human papillomavirus-16/18 AS04-adjuvanted vaccine in the United Kingdom.Acute Disseminated Encephalomyelitis Following Immunization with Human Papillomavirus Vaccines.To Consent or Decline HPV Vaccination: A Pilot Study at the Start of the National School-Based Vaccination Program in Sweden Safety of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in adolescents aged 12-15 years: Interim analysis of a large community-randomized controlled trial.Increased Serum Antibody Titer against HPV-16 Antigen in Patients with Behçet's Disease.Parents' views of including young boys in the Swedish national school-based HPV vaccination programme: a qualitative study.Human papillomavirus vaccination: where are we now?Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (gardasil(®)): a review of its use in the prevention of premalignant anogenital lesions, cervical and anal cancers, and genital warts.Cervical cancer screening at crossroads.The safety of human papilloma virus-blockers and the risk of triggering autoimmune diseases.9-Valent HPV vaccine for cancers, pre-cancers and genital warts related to HPV.Prophylactic HPV vaccination: past, present, and future.

P2860

Q26749285-A5EC66B9-52C0-4AE6-9212-B4B5C819F355 Q26799634-C194A24C-EC0C-462E-912E-9F067558AAF0 Q28072958-3F68A831-9216-4387-8553-6DD237336FE9 Q28079776-F2F5C721-0279-4E36-9B1B-7A4AA4F663B0 Q28081156-2B61C07A-3064-427A-A81F-0280F12CC8E8 Q28082119-50199B88-01FF-4917-B41E-C5082E86942C Q30275602-8486902C-7B82-4C5D-BFF4-9001B5A91AFB Q33166996-C95FDCA9-C8BE-4C67-AEA5-18F3C57E1C83 Q33167424-6AAF9E25-7D33-4A02-93BA-CFB3BAA97C2C Q33167702-3F2D3222-DDE6-4E5F-9604-782594DBF27E Q33419464-65184B99-E8CD-43AF-BC53-9D7FF76B67E6 Q33429171-6BD7DE93-8608-472B-AF4F-D38D62A9CAB1 Q33607120-5ED3535B-BEA4-4190-9A8F-AABA2E688CB3 Q33698095-A4013C1B-02B6-456A-AFF4-EFA8ADCC111F Q33772325-68F57D3A-F0BC-43CE-908A-C31E85F899AD Q33905320-9E84403D-8474-4C22-BDCD-C378F0B80ACA Q34507291-7AB9138F-96E8-4742-83D1-F76A7856EF8B Q34846745-2A20033A-F9CB-4671-A74F-FEF5FC017ABD Q35100677-73C861C4-629D-4690-9F0B-1C80E71A4D75 Q35546272-A26196B4-502D-4C6B-9677-AFA4C0259104 Q35548112-6D8316DC-19EF-41AB-92A3-E18EBF0FEE20 Q35666223-DAE725A6-01B4-42E9-8200-39B1DD4FCC17 Q35927665-919E5FEF-1B27-4B01-BDB5-A0946C6F6823 Q36127838-FD747D27-C071-465D-84CE-BF9BBDE45EC0 Q36457330-8E93D04C-D259-4D2F-A784-7C3E146B12D3 Q37135163-781A5F26-770F-480D-8F9D-1777B721C5C4 Q37135263-FC1A142A-15DD-4C49-8886-91204F153BDE Q37197029-1BE4F261-CCFC-478A-8F8B-6B01ED1B3986 Q37473234-2F47F59A-AF7D-4362-B53B-4567F7B7C9F6 Q37478850-DB9ADF9A-35E0-4AB0-840F-D1872792343E Q37505526-AE2A0BE5-E9A0-47ED-AA76-51254D3CB4EE Q37561432-2BFD9E43-29BB-40B3-B7C9-F0A5B568DBF1 Q37677720-89F73279-7B93-436B-8080-8BA5CFB32907 Q37681398-DB9138C6-7232-4C05-AF1A-C5B85336F3A9 Q38218612-593B83F7-6343-4EE3-BCAB-8EBD9D771FBF Q38229304-703FC0C7-BEF2-43E6-A7BC-D8721F72D13D Q38232145-B4497F31-87A4-4557-BE09-8C0F6DB7CB06 Q38555725-D7E9C46D-FFA9-4442-953E-7B2D70AA7F62 Q38586257-6EEBE0F6-8C03-454C-B77F-CF0F2522CE2A Q38597567-0552A13C-10CF-4C10-9744-BCD3C8EEE993

P2860

Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study

http://www.wikidata.org/entity/Q28300023

description

2013 nî lūn-bûn

@nan

2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Autoimmune, neurological, and ...... nmark and Sweden: cohort study

@ast

Autoimmune, neurological, and ...... nmark and Sweden: cohort study

@en

Autoimmune, neurological, and ...... nmark and Sweden: cohort study

@nl

type

label

Autoimmune, neurological, and ...... nmark and Sweden: cohort study

@ast

Autoimmune, neurological, and ...... nmark and Sweden: cohort study

@en

Autoimmune, neurological, and ...... nmark and Sweden: cohort study

@nl

prefLabel

Autoimmune, neurological, and ...... nmark and Sweden: cohort study

@ast

Autoimmune, neurological, and ...... nmark and Sweden: cohort study

@en

Autoimmune, neurological, and ...... nmark and Sweden: cohort study

@nl

P1433

Q28300023-105BE8BF-7E27-454B-B606-1B74427DB3D2

P1476

Q28300023-5841C87A-2F21-41CA-B247-D1DF48B7DEA9

P2093

Q28300023-31CF3A15-97B3-41CE-957C-68BDD09BADF0

Q28300023-84F74095-348A-424A-AED8-65BF82AB2201

P2860

Q28300023-0494C54D-CEDC-4898-A299-F5E03289E5B6

Q28300023-092E7C97-DA8E-496D-8748-46F5959A6851

Q28300023-1C089AED-6412-4915-A932-7FC912877FCA

Q28300023-2D7AB4EE-3D3C-4B96-BAA8-B9150EBEFD36

Q28300023-3844E3E5-EC07-4DA5-B9B9-469659026EFD

Q28300023-473C34D1-F364-4FE9-8AD8-D166EF79CACB

Q28300023-4C22E487-E99E-4044-9272-DB809F57AAFB

Q28300023-4F89782E-993D-4E34-8726-62E842B0275A

Q28300023-77F40634-7432-482A-A6F6-FBFC3B9A67A5

Q28300023-7BF15A08-2EC8-4827-8812-ABAD8DD9CFB3

P304

Q28300023-B48A5FD7-C7D6-4869-B901-C95C832075B7

P31

Q28300023-0CFF4B5C-33BB-4037-9FBF-E03F90DD759B

P3181

Q28300023-16CC1564-1FF1-414F-A4C6-1E353B873839

P356

Q28300023-20AE5395-EE6D-46F0-A0AA-E23E07FE6CAC

P407

Q28300023-27132D43-83BC-438A-85DD-B7752D7CA1CD

P433

Q28300023-2B0E1F91-3B4B-47D2-B9B0-919BAA2C24CA

P478

Q28300023-0D381E1D-21D4-4BE4-84A8-5D4CFCDAC7DC

P50

Q28300023-566C0609-6F24-41BE-8892-A7981AABB638

Q28300023-9C552720-94E0-456A-A26A-17F6C01074F8

Q28300023-C532749B-E9D5-45D0-A602-8BBBB7F1AEAC

P577

Q28300023-56CE21E8-70B2-4787-A511-5AB97AEF5692

P5875

Q28300023-BB8D0ADB-EDFB-4475-B1D0-50F9F1459149

P698

Q28300023-FCDA1F69-CB82-40D2-A7AD-6959A4543E06

P921

Q28300023-386329E7-1252-44B8-9966-48706307CBCE

Q28300023-9B3A243D-F423-4C48-A035-44EF8032B913

Q28300023-AEB5FA6F-5526-4DD6-84EE-DF4F53F5948F

P932

Q28300023-8BC69F88-523F-47D8-A288-C668CE4A61BA

P3181

P356

P1433

P1476

Autoimmune, neurological, and ...... nmark and Sweden: cohort study

@en

P2093

Henrik Svanström

http://www.w3.org/2001/XMLSchema#string

Pär Sparén

http://www.w3.org/2001/XMLSchema#string

P2860

The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research

Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine

AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland

Association between Guillain-Barré syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis.

Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink.

Safety of quadrivalent human papillomavirus vaccine administered routinely to females.

Use of population based background rates of disease to assess vaccine safety in childhood and mass immunisation in Denmark: nationwide population based cohort study.

Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis.

External review and validation of the Swedish national inpatient register.

Parental Knowledge, Attitudes, and Behaviours towards Human Papillomavirus Vaccination for Their Children: A Systematic Review from 2001 to 2011.

P304

f5906

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1959299

http://www.w3.org/2001/XMLSchema#string

P356

10.1136/BMJ.F5906

http://www.w3.org/2001/XMLSchema#string

P407

P433

oct09 4

http://www.w3.org/2001/XMLSchema#string

P478

347

http://www.w3.org/2001/XMLSchema#string

P50

Björn Pasternak

P577

2013-10-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

257599041

http://www.w3.org/2001/XMLSchema#string

P698

24108159

http://www.w3.org/2001/XMLSchema#string

P921

venous thromboembolism

P932

3805482

http://www.w3.org/2001/XMLSchema#string